Efficacy and Safety of Oropharyngeal Probiotic BP-OM1 on Respiratory Infection-Like Symptoms Among Patients With Lymphoma After Autologous Hematopoietic Stem Cell Transplantation: A Multicenter Randomized Controlled Pilot Study

IF 0.8 4区医学 Q4 IMMUNOLOGY

Transplantation proceedings Pub Date : 2025-03-26 DOI:10.1016/j.transproceed.2025.02.042

Xiaochen Xiang , Mingxin He , Xinquan Li , Jun Wang , Xiaojun Xu , Jingye Meng , Jialu Feng , Zhi Guo , Qiang Wang

{"title":"Efficacy and Safety of Oropharyngeal Probiotic BP-OM1 on Respiratory Infection-Like Symptoms Among Patients With Lymphoma After Autologous Hematopoietic Stem Cell Transplantation: A Multicenter Randomized Controlled Pilot Study","authors":"Xiaochen Xiang , Mingxin He , Xinquan Li , Jun Wang , Xiaojun Xu , Jingye Meng , Jialu Feng , Zhi Guo , Qiang Wang","doi":"10.1016/j.transproceed.2025.02.042","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Immune system impairment and chemotherapies prior to autologous hematopoietic stem cell transplantation (auto-HSCT) significantly increase the risk of respiratory tract infections (RTIs), especially within 100 days after HSCT. Prophylaxis of RTIs among patients with HSCT are of high importance, clinical experiences have been learnt previously that oropharyngeal probiotic is safe and able to significantly reduce RTIs among patients with recurrent RTIs in both children and adults, the aim of this study is to explore the safety and preventive effects of oropharyngeal probiotics BP-OM1 on RTIs among patients after HSCT.</div></div><div><h3>Methods</h3><div>Sixteen subjects aged between 18 and 65 years old who underwent HSCT were enrolled in a multicenter, randomized controlled trial. The subjects were randomly assigned to the oropharyngeal probiotics group and the control group. Patients were intervened and monitored for 130 days.</div></div><div><h3>Results</h3><div>Less duration and severity of presented RTI-like symptoms observed among patients in the probiotic group resulted in a significantly decreased days of antibiotic consumption post-HSCT. No oropharyngeal probiotic-related adverse events were reported throughout this study, indicating that oropharyngeal probiotic BP-OM1 administration is safe for patients whose hematopoietic system are well reconstructed post-HSCT.</div></div><div><h3>Conclusions</h3><div>The administration of oropharyngeal probiotic BP-OM1 could potentially be a safe self-care approach for patients who underwent HSCT to manage the RTI prevention and reduce the risks of developing lower respiratory tract infection (LRTI), which favors the rational use of antibiotics, which is associated with a reduced risks colonization of multi-drug resistance microorganisms.</div></div>","PeriodicalId":23246,"journal":{"name":"Transplantation proceedings","volume":"57 4","pages":"Pages 627-637"},"PeriodicalIF":0.8000,"publicationDate":"2025-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Transplantation proceedings","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0041134525001307","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Immune system impairment and chemotherapies prior to autologous hematopoietic stem cell transplantation (auto-HSCT) significantly increase the risk of respiratory tract infections (RTIs), especially within 100 days after HSCT. Prophylaxis of RTIs among patients with HSCT are of high importance, clinical experiences have been learnt previously that oropharyngeal probiotic is safe and able to significantly reduce RTIs among patients with recurrent RTIs in both children and adults, the aim of this study is to explore the safety and preventive effects of oropharyngeal probiotics BP-OM1 on RTIs among patients after HSCT.

Methods

Sixteen subjects aged between 18 and 65 years old who underwent HSCT were enrolled in a multicenter, randomized controlled trial. The subjects were randomly assigned to the oropharyngeal probiotics group and the control group. Patients were intervened and monitored for 130 days.

Results

Less duration and severity of presented RTI-like symptoms observed among patients in the probiotic group resulted in a significantly decreased days of antibiotic consumption post-HSCT. No oropharyngeal probiotic-related adverse events were reported throughout this study, indicating that oropharyngeal probiotic BP-OM1 administration is safe for patients whose hematopoietic system are well reconstructed post-HSCT.

Conclusions

The administration of oropharyngeal probiotic BP-OM1 could potentially be a safe self-care approach for patients who underwent HSCT to manage the RTI prevention and reduce the risks of developing lower respiratory tract infection (LRTI), which favors the rational use of antibiotics, which is associated with a reduced risks colonization of multi-drug resistance microorganisms.

查看原文本刊更多论文

口咽益生菌BP-OM1对自体造血干细胞移植后淋巴瘤患者呼吸道感染样症状的疗效和安全性：一项多中心随机对照先导研究

背景：自体造血干细胞移植（auto-HSCT）前的免疫系统损伤和化疗显著增加呼吸道感染（RTIs）的风险，特别是在HSCT后100天内。HSCT患者RTIs的预防非常重要，先前的临床经验表明口咽益生菌是安全的，能够显著减少儿童和成人复发性RTIs患者的RTIs，本研究的目的是探讨口咽益生菌BP-OM1对HSCT后患者RTIs的安全性和预防作用。方法：16名年龄在18岁至65岁之间接受HSCT的患者被纳入一项多中心随机对照试验。受试者被随机分为口咽益生菌组和对照组。对患者进行干预和监测130天。结果：在益生菌组患者中观察到的rti样症状持续时间和严重程度较短，导致hsct后抗生素使用天数显着减少。本研究未见口咽益生菌相关不良事件的报道，表明对于造血系统重建良好的hsct患者，口咽益生菌BP-OM1给药是安全的。结论：口咽益生菌BP-OM1可能是HSCT患者预防RTI和降低发生下呼吸道感染（LRTI）风险的一种安全的自我护理方法，有利于合理使用抗生素，这与降低多重耐药微生物的定植风险有关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Transplantation proceedings 医学-免疫学

CiteScore

1.70

自引率

0.00%

发文量

502

审稿时长

60 days

期刊介绍： Transplantation Proceedings publishes several different categories of manuscripts, all of which undergo extensive peer review by recognized authorities in the field prior to their acceptance for publication. The first type of manuscripts consists of sets of papers providing an in-depth expression of the current state of the art in various rapidly developing components of world transplantation biology and medicine. These manuscripts emanate from congresses of the affiliated transplantation societies, from Symposia sponsored by the Societies, as well as special Conferences and Workshops covering related topics. Transplantation Proceedings also publishes several special sections including publication of Clinical Transplantation Proceedings, being rapid original contributions of preclinical and clinical experiences. These manuscripts undergo review by members of the Editorial Board. Original basic or clinical science articles, clinical trials and case studies can be submitted to the journal?s open access companion title Transplantation Reports.